Arecor

Market:

Unlisted (UK)

Market Cap:

-

Price

-

Change

-

52 weeks high

-

52 weeks low

-

09.31

Director Interviews

In brief

Arecor is ‘advancing today’s therapies to enable healthier lives’ by developing a broad portfolio of therapies for its proprietary pipeline and in partnership with leading pharmaceutical and biotech companies

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

Arecor advancing today’s therapies to enable healthier lives

Arecor -

Snapshot

Arecor uses its ground-breaking technology platform, Arestat™ to develop future medicines from existing therapies, across all disease indications and at any stage of a drug lifecycle
Proprietary portfolio includes first franchise in diabetes and has expanded its development pipeline into anti-infectives
Partners with leading pharmaceutical and biotech companies to improve their products, find solutions or create next-generation products

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Arecor -

Arecor punches above its weight with trials for fast-acting diabetes drugs

Investors are placing bets on a small British biotech to rival big pharma as it pushes its first diabetes drug through clinical trials

on 14/11/19

Interviews

Arecor - Arecor CEO updates as data for lead insulin product is presented at American Diabetes Association

Health Arecor CEO updates as data for lead insulin product is presented at American Diabetes Association

on 15/6/20

Arecor - Arecor's Sarah Howell discusses results from successful phase I insulin trial

Health Arecor's Sarah Howell discusses results from successful phase I insulin trial

on 17/12/19

Arecor - Arecor completes dosing in its Phase I clinical trial and secures key partnership

Health Full interview: Arecor completes dosing in its Phase I clinical trial and secures key partnership

on 6/11/19

Health Arecor doses first patient in Phase I trial for ultra-rapid acting insulin product

on 7/5/19

Follow us on:

© Proactive Investors 2019.

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use.